Investors
and Media
News Releases
-
Jul 17, 2019
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2019, and...
-
Jul 8, 2019- Data Presented at the Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH 2019) -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new invitro data establishing the relationship between concentrations of the direct oral anticoagulants (DOACs) apixaban and...
-
Jun 19, 2019- Interim Phase 2a Data Highlight Efficacy and Safety Results of Cerdulatinib Alone and in Combination with Rituximab -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...
-
May 28, 2019
May 28, 2019 PDF Version SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and...
-
May 22, 2019– Excellent or Good Hemostasis Achieved in 79% of Evaluable Patients with Spontaneous Intracranial Hemorrhage –
SOUTH SAN FRANCISCO, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of a new analysis of data from an important subgroup...